Qiagen N.V., a leading global provider of sample to insight solutions, announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the world’s first complete Sample to Insight solution making the benefits of next-generation sequencing (NGS) accessible to any laboratory.
Qiagen published new, excellent performance data of the Qiagen GeneReader NGS System using the new sequencing chemistry and Qiagen’s GeneRead QIAact Actionable Insights Tumor Panel. Data generated from the GeneReader NGS System with the new chemistry showed 100% concordance with results of Qiagen’s FDA approved therascreen KRAS RGQ PCR assay, the company’s CE-labelled therascreen RAS Extension Pyro Assay as well as with an alternative next-generation sequencing (NGS) sequencer from another vendor. In this study, 42 metastatic colorectal cancer FFPE samples were tested with previously confirmed RAS mutational status.